- Accueil
- 98 054 508 ds
- G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges
G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges
4.6 (372) · € 24.00 · En Stock
Deciphering G-Protein-Coupled Receptor 119 Agonists as Promising Strategy against Type 2 Diabetes Using Systems Biology Approach
Activation and signaling mechanism revealed by GPR119-Gs complex structures
Full article: GPR119 agonists for the treatment of type 2 diabetes: an updated patent review (2014-present)
Figure 2 from GPR119 Agonists: A Novel Strategy for Type 2 Diabetes Treatment
Targeting GPCRs Activated by Fatty Acid-Derived Lipids in Type 2 Diabetes: Trends in Molecular Medicine
Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II Diabetes. - Abstract - Europe PMC
Pharmacogenomic Studies of Current Antidiabetic Agents and Potential New Drug Targets for Precision Medicine of Diabetes
PDF) First GPR119 PET Imaging Ligand: Synthesis, Radiochemistry, and Preliminary Evaluations
Biased signaling of lipids and allosteric actions of synthetic molecules for GPR119 - ScienceDirect
Frontiers Structure of human GPR119-Gs complex binding APD597 and characterization of GPR119 binding agonists
PDF] G Protein–Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus
Pharmacotherapy of type 2 diabetes: An update and future directions - Metabolism - Clinical and Experimental
G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges
PDF] G Protein–Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus
Activation and signaling mechanism revealed by GPR119-Gs complex structures
